Cureus

1. KAYE AD, Perilloux DM, Field E, Orvin CA, et al
   Rabies Vaccine for Prophylaxis and Treatment of Rabies: A Narrative Review.
   Cureus. 2024;16:e62429.
   

   >> Share

   
   

   
   F1000Res

2. SURENDRAN J, Hs R, Kumari N, M Prasanth R, et al
   A prospective study on health seeking behaviour and post exposure prophylaxis received by animal bite victims at the anti-rabies clinic in a tertiary care centre of urban Bangalore.
   F1000Res. 2024;13:175.
   

   >> Share

   
   

   
   Infect Disord Drug Targets

3. NEHRU S, Thangaraju P, Cibee N, Velmurugan H, et al
   Dog Bite Injury: Rusk Became a Risk - A Case Report.
   Infect Disord Drug Targets. 2024;24:e250124226174.
   

   >> Share

   
   

   
   J Travel Med

4. MARTINEZ GE, Richter J, Hammer J, Castillo MCM, et al
   Do Seal Bites Require Rabies Post-Exposure Prophylaxis?
   J Travel Med. 2024 Jul 20:taae098. doi: 10.1093.
   

   >> Share

   
   

   
   PLoS Negl Trop Dis

5. MSHELBWALA PP, Wangdi K, Bunting-Graden JA, Bamayange S, et al
   Insights into canine rabies vaccination Disparities in Sierra Leone: A cross-sectional household study.
   PLoS Negl Trop Dis. 2024;18:e0012332.
   

   >> Share

   
   

   
   Travel Med Infect Dis

6. OVERDUIN LA, Koopman JPR, Prins C, Verbeek-Menken PH, et al
   Rabies knowledge gaps and risk behaviour in Dutch travellers: An observational cohort study.
   Travel Med Infect Dis. 2024;60:102739.
   

   >> Share

   
   

   
   Trop Med Health

7. ATUHEIRE CGK, Okwee-Acai J, Taremwa M, Terence O, et al
   Descriptive analyses of knowledge, attitudes, and practices regarding rabies transmission and prevention in rural communities near wildlife reserves in Uganda: a One Health cross-sectional study.
   Trop Med Health. 2024;52:48.
   

   >> Share

   
   

   
   Vaccine

8. JIN F, Zhu L, Wang Y, Qin G, et al
   Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].
   Vaccine. 2024 Jul 16:S0264-410X(24)00791-6. doi: 10.1016/j.vaccine.2024.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share